Peer-reviewed veterinary case report
Chemotherapy with carboplatin and cytarabine for dogs with relapsed
By Gillem, J et al.·Published in Veterinary and comparative oncology·2017·Department of Clinical Studies, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Efficacy and toxicity of carboplatin and cytarabine chemotherapy for dogs with relapsed or refractory lymphoma (2000-2013).
- Species:
- dog
Plain-English summary
A group of 22 dogs with relapsed lymphoma (a type of cancer) received chemotherapy treatments with either carboplatin alone or a combination of carboplatin and cytarabine. While only 18.2% of the dogs showed a positive response to the treatment, those that did respond had a median survival time of 109 days, compared to just 21 days for non-responders. However, many dogs experienced significant side effects, including low platelet and white blood cell counts. Despite the high toxicity, the combination treatment may still be a viable option for some dogs when managed with supportive care.
People also search for: dog lymphoma treatment options · carboplatin side effects in dogs · cytarabine for dog cancer
Abstract
Medical records of 22 dogs treated with carboplatin (n = 8) or carboplatin and cytarabine (n = 14) chemotherapy for relapsed or refractory lymphoma between 2000 and 2013 were retrospectively reviewed. The clinical response rate was 18.2% (4/22). Median time to progression was 18 days (56 for responders; 12 for non-responders, P = 0.0006). Median overall survival time was 28 days (109 for responders; 21 for non-responders, P = 0.0007). Thrombocytopenia and neutropenia occurred in 84.2% (16/19) and 52.6% (10/19), respectively. Grade IV thrombocytopenia and neutropenia occurred in 56.3% (9/16) and 60.0% (6/10), respectively. Dogs that received both drugs were more likely to become neutropenic (P = 0.022) or thrombocytopenic (P = 0.001) than dogs receiving carboplatin alone. All responders received both drugs giving a 28.6% (4/14) response rate for the combination. Although some dogs responded to the combination, toxicity was high and the responses were not durable. With adequate supportive care, this protocol may be an acceptable rescue option for some dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/26463827/